SCHEMBL366654

SCHEMBL366654

CCCC1CCc2nn(Cc3ccc(OC)cc3)cc2C1=O

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AADAT Q8N5Z0 1/20 0.44
CYP24A1 Q07973 3/20 0.40
CYP26A1 O43174 1/20 0.40
CYP19A1 P11511 2/20 0.38
CMA1 P23946 1/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GAA P10253 1/20 0.36
CYP27A1 Q02318 1/20 0.36
GSK3A P49840 2/20 0.36
GSK3B P49841 2/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL366125 0.85 AADAT (0.43) AADATCYP24A1CYP26A1CYP19A1CMA1
SCHEMBL15182499 0.84 AADAT (0.47) AADATCMA1GAAGSK3AGSK3B
SCHEMBL365074 0.83 AADAT (0.43) AADATCYP24A1CYP26A1CMA1GAA
SCHEMBL365853 0.79 AADAT (0.45) AADATCMA1GAAGSK3AGSK3B
SCHEMBL6837143 0.79 AADAT (0.45) AADATCMA1CYP3A4CYP2C9GAA
SCHEMBL6837301 0.77 ALDH1A1 (0.48) AADATCMA1NPSR1GAAGSK3A
SCHEMBL365659 0.77 ALDH1A1 (0.48) AADATCMA1NPSR1GAAGSK3A
SCHEMBL7670133 0.72 AADAT (0.47) AADATCMA1NPSR1GAAGSK3A
SCHEMBL366071 0.72 AADAT (0.50) AADATCMA1CYP3A4NPSR1GAA
SCHEMBL365744 0.72 AADAT (0.47) AADATCMA1NPSR1GAAGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 AADAT 837/4885CYP24A1 2006/4885CYP26A1 2448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.